Researchers took both the learning curve of the new process and the COVID-19 pandemic into consideration.
A new cost analysis found some evidence that the initial increased costs associated with robot-assisted thoracoscopic surgery (RATS) lung resection may be gradually offset as a program progresses.
Findings were published in Frontiers in Surgery.
“In the 1990s, video-assisted thoracoscopic surgery (VATS) was introduced and became the standard surgical approach offered for the treatment of early-stage lung cancer,” authors wrote.
However, over the last 2 decades, RATS has entered the thoracic surgical practice and several studies have shown this process may have benefits over VATS. These include better lymph node dissection, less blood loss, higher complete resection rate, lower conversion rate, less postoperative complications, and better quality of life.
Still, concerns remain about the increased cost of RATS compared with VATS.
“Due to a lack of randomized trials, there is still an open debate regarding the best and most cost-effective minimally invasive approach in the treatment of lung neoplasms,” the researchers explained.
To better understand the impact of the learning curve on the cost-effectiveness of RATS vs VATS lung resection and analyze the impact of the COVID-19 pandemic on postoperative costs in patients with minimally invasive lung cancer surgery, the investigators assessed 365 consecutive RATS lung resections. They noted that their center is the highest-volume thoracic unit for lung cancer resection in the UK National Health Service.
Of the 365 consecutive RATS lung resections included in this analysis, 36.2% were male patients, and the median age was 71 years. Nearly 98% of patients underwent an anatomical lung resection. All patients underwent RATS between January 2017 and December 2020.
The researchers also analyzed a matched cohort of VATS cases. To assess the learning curve, they compared the first 100 and most recent 100 RATS cases performed at their institution.
Analyses revealed:
Median operating time was 127 minutes for patients undergoing RATS. Just 6 patients required a blood transfusion, and 19 patients required an unplanned intensive care unit admission.
“Passing the learning curve is associated with a significant reduction in the theatre costs associated with RATS lung resection and is comparable with the cost of VATS,” the authors wrote.
However, they noted the current analysis may underestimate the true cost benefit of passing the learning curve thanks to the effect of the pandemic on theatre costs.
“The COVID-19 pandemic made RATS lung resection more expensive due to prolonged hospital stay and increased readmission rate,” researchers wrote.
This study is the first to their knowledge that demonstrates the effect of the learning curve on cost of RATS lung resection.
The observational study included a disproportionately high number of robotic procedures performed during the COVID-19 pandemic, which may have introduced bias and marks a limitation.
“In conclusion, prior to passing the learning curve, RATS lung resection is associated with increased average procedure cost. When the learning curve is passed, theatre costs become significantly lower and are comparable with VATS,” the researchers wrote. “The true postoperative costs of RATS surgery may be similar or even lower than VATS; however, further studies are required to elucidate this.”
Reference
Harrison OJ, Maraschi A, Routledge T, Lampridis S, LeReun C, Bille A. A cost analysis of robotic vs. video-assisted thoracic surgery: the impact of the learning curve and the COVID-19 pandemic. Front Surg. Published online April 25, 2023. doi:10.3389/fsurg.2023.1123329
Study Highlights Significant Increases in Utilization, Spending on DMD Drugs in Medicaid
May 17th 2024The findings add to recent research on the growing utilization, expenditure, and prices of Duchenne muscular dystrophy (DMD) therapies in the current landscape, an area health care policy could potentially address.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Bleeds and Resource Use in Hemophilia B: Retrospective Observational Study
May 15th 2024This real-world US study describes individuals with hemophilia B who experience bleeds despite factor replacement therapy and quantifies the associated comorbidity and health care resource utilization burden.
Read More
A new study highlights significant disparity in reimbursement rates across states between hospitals and Medicare; the first patient to receive a genetically modified pig kidney has died; research examines outcomes of over 500 patients receiving medication abortion pills by mail.
Read More